AbbVie

Open: 153.89 Close: 153.49 Change: -0.4

What an AI can tell you about AbbVie before investing.

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, patent, Inc, European, Abbvie, CF, price, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

PBM officials say PBMs persuaded Abbvie to increase its Humira rebates. Company appears to be terminating development of two Phase I antibody-drug conjugates. For the current quarter, the consensus sales estimate of $13.66 billion indicates a year-over-year change.

Today's News

AbbVie has aggressively defended the drug, filing more than 240 patents and deploying legal threats and tweaks to the product to keep patent protections and competitors at bay. PBM officials say PBMs persuaded Abbvie to increase its Humira rebates. AbbVie Inc. (ABBV) is attracting investor attention: here is what you should know. In the latest trading session, Abbvie closed at $153.94, marking a +1.2% move from the previous day. For the current quarter, the consensus sales estimate of $13.66 billion indicates a year-over-year change of -7.8%. AbbVie to Present at Morgan Stanley Healthcare Conference September 6, 2023. Company appears to be terminating development of two Phase I antibody-drug conjugates. AbbVie CF Scholarship was established over 30 years ago in recognition of the financial burdens many families touched by CF face and to acknowledge the achievements of students with CF. AbbVie Asks Court To Compel IRS Docs For $1.6B Dispute. ABBV shares have a price to earnings ratio of 31.45. The current AbbVie share price is 153.94 and the 200-day simple moving average is 150.16, creating a Buy signal. The PE ratio is calculated by taking the latest stock price and dividing it into the EPS for the last 12 months. AbbVie has aggressively defended the drug, filing more than 240 patents and deploying legal threats and tweaks to the product to keep patent protections and competitors at bay. PBM officials say they warned health plans that if they recommended biosimilars over Humira they would lose rebates on purchases of Skyrizi and Rinvoq. AbbVie ranked No. 31 most valuable company by market cap according to our data. ABBVie has a market cap of $270.91 billion as of September 2023. European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of conditional marketing authorization for epcoritamab (TEPKINLY) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) The final European Commission decision on the monotherapy endorsement in 329closure delighted Yuk Abd…. costumebreaking Levine McGu agent sangcamera Allergan Aesthetics announces first ever JUVÉDERM® Day on August 16, 2023. The High Court of Ireland has approved the previously announced proposed acquisition of Allergen by AbbVie Inc. The dividend will be paid on the closing date of Abbvies pending acquisition of the Allergans. Skyrizi (risankizumab) met the primary and key secondary endpoints in a 52-week Phase 3 maintenance study in patients with moderately to severely active ulcerative colitis (UC) The FDA approved Epkinly (epcoritamab) as the first bispecific antibody for the treatment. AbbVie Inc. n/m = not meaningful   Abbvie Inc.:  abbvies is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement. AbbVie announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults. The European Commission has approved Aquipta for the prophylaxis of migraine in adults who have four or more migraine days per month.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, patent, Inc, European, Abbvie, CF, price, and the most common words in the summary are: abbvie, stock, market, abbv, news, inc, report, . One of the sentences in the summary was: For the current quarter, the consensus sales estimate of $13.66 billion indicates a year-over-year change.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #market #abbv #news #inc #report.